nodes	percent_of_prediction	percent_of_DWPC	metapath
Amiloride—PLAU—endothelium—colon cancer	0.0282	0.0586	CbGeAlD
Amiloride—PLAU—blood vessel—colon cancer	0.026	0.054	CbGeAlD
Amiloride—AOC1—embryo—colon cancer	0.0171	0.0355	CbGeAlD
Amiloride—SLC9A1—embryo—colon cancer	0.0163	0.034	CbGeAlD
Amiloride—SCNN1D—epithelium—colon cancer	0.0142	0.0295	CbGeAlD
Amiloride—SLC9A1—epithelium—colon cancer	0.0133	0.0277	CbGeAlD
Amiloride—SCNN1G—renal system—colon cancer	0.0132	0.0274	CbGeAlD
Amiloride—AOC1—renal system—colon cancer	0.0129	0.0269	CbGeAlD
Amiloride—SLC9A1—smooth muscle tissue—colon cancer	0.0129	0.0267	CbGeAlD
Amiloride—PLAU—epithelium—colon cancer	0.0126	0.0263	CbGeAlD
Amiloride—SLC9A1—renal system—colon cancer	0.0124	0.0257	CbGeAlD
Amiloride—PLAU—smooth muscle tissue—colon cancer	0.0122	0.0253	CbGeAlD
Amiloride—SCNN1B—epithelium—colon cancer	0.012	0.0249	CbGeAlD
Amiloride—PLAU—renal system—colon cancer	0.0117	0.0244	CbGeAlD
Amiloride—SCNN1B—renal system—colon cancer	0.0111	0.0231	CbGeAlD
Amiloride—SCNN1A—epithelium—colon cancer	0.0111	0.023	CbGeAlD
Amiloride—AOC1—digestive system—colon cancer	0.0106	0.022	CbGeAlD
Amiloride—SLC9A1—lymphoid tissue—colon cancer	0.0103	0.0214	CbGeAlD
Amiloride—SCNN1A—renal system—colon cancer	0.0103	0.0214	CbGeAlD
Amiloride—SLC9A1—Defective B3GAT3 causes JDSSDHD—CHST5—colon cancer	0.0102	0.0483	CbGpPWpGaD
Amiloride—SLC9A1—digestive system—colon cancer	0.0101	0.0211	CbGeAlD
Amiloride—AOC1—bone marrow—colon cancer	0.00977	0.0203	CbGeAlD
Amiloride—PLAU—lymphoid tissue—colon cancer	0.00974	0.0203	CbGeAlD
Amiloride—PLAU—digestive system—colon cancer	0.00962	0.02	CbGeAlD
Amiloride—SCNN1G—vagina—colon cancer	0.00953	0.0198	CbGeAlD
Amiloride—AOC1—vagina—colon cancer	0.00936	0.0195	CbGeAlD
Amiloride—SLC9A1—bone marrow—colon cancer	0.00936	0.0195	CbGeAlD
Amiloride—PLAU—bone marrow—colon cancer	0.00887	0.0184	CbGeAlD
Amiloride—PLAU—vagina—colon cancer	0.0085	0.0177	CbGeAlD
Amiloride—SCNN1A—digestive system—colon cancer	0.00843	0.0175	CbGeAlD
Amiloride—SCNN1B—vagina—colon cancer	0.00805	0.0167	CbGeAlD
Amiloride—SCNN1D—liver—colon cancer	0.00804	0.0167	CbGeAlD
Amiloride—AOC1—liver—colon cancer	0.00789	0.0164	CbGeAlD
Amiloride—SLC9A1—liver—colon cancer	0.00756	0.0157	CbGeAlD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—AXIN2—colon cancer	0.0075	0.0354	CbGpPWpGaD
Amiloride—SLC22A2—Abacavir transmembrane transport—ABCB1—colon cancer	0.00739	0.0349	CbGpPWpGaD
Amiloride—PLAU—liver—colon cancer	0.00717	0.0149	CbGeAlD
Amiloride—SLC22A1—Abacavir transmembrane transport—ABCB1—colon cancer	0.00689	0.0325	CbGpPWpGaD
Amiloride—SCNN1A—liver—colon cancer	0.00628	0.0131	CbGeAlD
Amiloride—SCNN1D—lymph node—colon cancer	0.00617	0.0128	CbGeAlD
Amiloride—AOC1—lymph node—colon cancer	0.00605	0.0126	CbGeAlD
Amiloride—ASIC1—lymph node—colon cancer	0.00605	0.0126	CbGeAlD
Amiloride—Encephalopathy—Fluorouracil—colon cancer	0.00596	0.0194	CcSEcCtD
Amiloride—SLC9A1—lymph node—colon cancer	0.0058	0.0121	CbGeAlD
Amiloride—Heartburn—Fluorouracil—colon cancer	0.00556	0.0181	CcSEcCtD
Amiloride—SLC22A2—renal system—colon cancer	0.00555	0.0115	CbGeAlD
Amiloride—PLAU—lymph node—colon cancer	0.0055	0.0114	CbGeAlD
Amiloride—SLC9A1—Carbohydrate metabolism—CHST5—colon cancer	0.00549	0.0259	CbGpPWpGaD
Amiloride—SCNN1B—lymph node—colon cancer	0.00521	0.0108	CbGeAlD
Amiloride—SCNN1A—lymph node—colon cancer	0.00481	0.01	CbGeAlD
Amiloride—SLC22A2—digestive system—colon cancer	0.00455	0.00946	CbGeAlD
Amiloride—Hyperuricaemia—Vincristine—colon cancer	0.00442	0.0144	CcSEcCtD
Amiloride—SLC22A2—Abacavir transport and metabolism—ABCB1—colon cancer	0.00424	0.02	CbGpPWpGaD
Amiloride—Blood uric acid increased—Vincristine—colon cancer	0.00418	0.0136	CcSEcCtD
Amiloride—Encephalopathy—Capecitabine—colon cancer	0.00416	0.0136	CcSEcCtD
Amiloride—SLC22A4—renal system—colon cancer	0.00412	0.00856	CbGeAlD
Amiloride—SLC22A1—Abacavir transport and metabolism—ABCB1—colon cancer	0.00396	0.0187	CbGpPWpGaD
Amiloride—SLC9A1—Signaling mediated by p38-alpha and p38-beta—PTGS2—colon cancer	0.00394	0.0186	CbGpPWpGaD
Amiloride—SLC22A1—renal system—colon cancer	0.00392	0.00815	CbGeAlD
Amiloride—Coma—Vincristine—colon cancer	0.00375	0.0122	CcSEcCtD
Amiloride—Urine output increased—Vincristine—colon cancer	0.00371	0.0121	CcSEcCtD
Amiloride—PLAU—FGF signaling pathway—FGFR3—colon cancer	0.0036	0.017	CbGpPWpGaD
Amiloride—PLAU—E2F transcription factor network—TYMS—colon cancer	0.00354	0.0167	CbGpPWpGaD
Amiloride—PLAU—ATF-2 transcription factor network—BCL2L1—colon cancer	0.00351	0.0166	CbGpPWpGaD
Amiloride—Coma—Fluorouracil—colon cancer	0.0035	0.0114	CcSEcCtD
Amiloride—Polyuria—Vincristine—colon cancer	0.00339	0.011	CcSEcCtD
Amiloride—SLC22A4—digestive system—colon cancer	0.00338	0.00702	CbGeAlD
Amiloride—PLAU—Endochondral Ossification—FGFR3—colon cancer	0.00315	0.0148	CbGpPWpGaD
Amiloride—SLC22A4—bone marrow—colon cancer	0.00311	0.00647	CbGeAlD
Amiloride—Encephalopathy—Methotrexate—colon cancer	0.0031	0.0101	CcSEcCtD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCND1—colon cancer	0.00307	0.0145	CbGpPWpGaD
Amiloride—Visual disturbance—Irinotecan—colon cancer	0.00306	0.00996	CcSEcCtD
Amiloride—PLAU—FGF signaling pathway—CDH1—colon cancer	0.00304	0.0144	CbGpPWpGaD
Amiloride—Hyponatraemia—Vincristine—colon cancer	0.00299	0.00973	CcSEcCtD
Amiloride—SLC22A4—vagina—colon cancer	0.00298	0.0062	CbGeAlD
Amiloride—Pain in extremity—Vincristine—colon cancer	0.00298	0.0097	CcSEcCtD
Amiloride—Liver disorder—Methotrexate—colon cancer	0.00292	0.00951	CcSEcCtD
Amiloride—Hyponatraemia—Irinotecan—colon cancer	0.00291	0.00948	CcSEcCtD
Amiloride—Gastrointestinal haemorrhage—Irinotecan—colon cancer	0.0029	0.00944	CcSEcCtD
Amiloride—SLC22A1—vagina—colon cancer	0.00284	0.0059	CbGeAlD
Amiloride—PLAU—Validated transcriptional targets of AP1 family members Fra1 and Fra2—EP300—colon cancer	0.00283	0.0133	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway—APC—colon cancer	0.00278	0.0131	CbGpPWpGaD
Amiloride—Gastrointestinal haemorrhage—Fluorouracil—colon cancer	0.00278	0.00904	CcSEcCtD
Amiloride—Neck pain—Capecitabine—colon cancer	0.00271	0.00881	CcSEcCtD
Amiloride—Orthostatic hypotension—Irinotecan—colon cancer	0.00265	0.00862	CcSEcCtD
Amiloride—Muscular weakness—Vincristine—colon cancer	0.00263	0.00855	CcSEcCtD
Amiloride—Cramp muscle—Irinotecan—colon cancer	0.00261	0.0085	CcSEcCtD
Amiloride—Abdominal distension—Irinotecan—colon cancer	0.00252	0.00822	CcSEcCtD
Amiloride—PLAU—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—SRC—colon cancer	0.00248	0.0117	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—BAX—colon cancer	0.00248	0.0117	CbGpPWpGaD
Amiloride—SLC9A1—ErbB1 downstream signaling—BCL2L1—colon cancer	0.00246	0.0116	CbGpPWpGaD
Amiloride—Muscular weakness—Fluorouracil—colon cancer	0.00245	0.00798	CcSEcCtD
Amiloride—Angina pectoris—Irinotecan—colon cancer	0.00244	0.00795	CcSEcCtD
Amiloride—Urine output increased—Capecitabine—colon cancer	0.00242	0.00787	CcSEcCtD
Amiloride—PLAU—Osteopontin-mediated events—PIK3CA—colon cancer	0.00241	0.0114	CbGpPWpGaD
Amiloride—Dysuria—Vincristine—colon cancer	0.00241	0.00784	CcSEcCtD
Amiloride—Neutropenia—Vincristine—colon cancer	0.00241	0.00784	CcSEcCtD
Amiloride—SLC22A1—liver—colon cancer	0.00239	0.00498	CbGeAlD
Amiloride—PLAU—Beta3 integrin cell surface interactions—VEGFA—colon cancer	0.00237	0.0112	CbGpPWpGaD
Amiloride—Erectile dysfunction—Vincristine—colon cancer	0.00237	0.00772	CcSEcCtD
Amiloride—SLC9A1—Signaling mediated by p38-alpha and p38-beta—TP53—colon cancer	0.00234	0.0111	CbGpPWpGaD
Amiloride—Neutropenia—Irinotecan—colon cancer	0.00234	0.00763	CcSEcCtD
Amiloride—Angina pectoris—Fluorouracil—colon cancer	0.00234	0.00761	CcSEcCtD
Amiloride—Depression—Vincristine—colon cancer	0.00229	0.00745	CcSEcCtD
Amiloride—PLAU—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—TGFB1—colon cancer	0.00222	0.0105	CbGpPWpGaD
Amiloride—Hepatic function abnormal—Capecitabine—colon cancer	0.00222	0.00723	CcSEcCtD
Amiloride—Polyuria—Capecitabine—colon cancer	0.00221	0.0072	CcSEcCtD
Amiloride—Jaundice—Irinotecan—colon cancer	0.00218	0.00709	CcSEcCtD
Amiloride—PLAU—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—EGFR—colon cancer	0.00218	0.0103	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—CA7—colon cancer	0.00215	0.0101	CbGpPWpGaD
Amiloride—Hyperuricaemia—Methotrexate—colon cancer	0.00215	0.00699	CcSEcCtD
Amiloride—PLAU—ATF-2 transcription factor network—CCND1—colon cancer	0.00211	0.00997	CbGpPWpGaD
Amiloride—Libido decreased—Capecitabine—colon cancer	0.00209	0.00681	CcSEcCtD
Amiloride—Bradycardia—Irinotecan—colon cancer	0.00204	0.00665	CcSEcCtD
Amiloride—Thirst—Capecitabine—colon cancer	0.00204	0.00664	CcSEcCtD
Amiloride—PLAU—FGF signaling pathway—SRC—colon cancer	0.00203	0.00958	CbGpPWpGaD
Amiloride—Blood uric acid increased—Methotrexate—colon cancer	0.00203	0.0066	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—BRAF—colon cancer	0.00203	0.00955	CbGpPWpGaD
Amiloride—Haemoglobin—Irinotecan—colon cancer	0.00202	0.00657	CcSEcCtD
Amiloride—Haemorrhage—Irinotecan—colon cancer	0.00201	0.00653	CcSEcCtD
Amiloride—SLC9A1—Endothelins—SRC—colon cancer	0.00199	0.00939	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—APC—colon cancer	0.00199	0.00938	CbGpPWpGaD
Amiloride—Hyponatraemia—Capecitabine—colon cancer	0.00195	0.00634	CcSEcCtD
Amiloride—PLAU—ATF-2 transcription factor network—EP300—colon cancer	0.00195	0.00918	CbGpPWpGaD
Amiloride—Pain in extremity—Capecitabine—colon cancer	0.00194	0.00632	CcSEcCtD
Amiloride—Gastrointestinal haemorrhage—Capecitabine—colon cancer	0.00194	0.00632	CcSEcCtD
Amiloride—Visual impairment—Irinotecan—colon cancer	0.00193	0.00629	CcSEcCtD
Amiloride—Haemoglobin—Fluorouracil—colon cancer	0.00193	0.00629	CcSEcCtD
Amiloride—SLC22A4—lymph node—colon cancer	0.00193	0.00401	CbGeAlD
Amiloride—Disturbance in sexual arousal—Capecitabine—colon cancer	0.00192	0.00627	CcSEcCtD
Amiloride—Haemorrhage—Fluorouracil—colon cancer	0.00192	0.00626	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway—CCND1—colon cancer	0.00191	0.00901	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway—CTNNB1—colon cancer	0.00189	0.00892	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—APC—colon cancer	0.00189	0.0089	CbGpPWpGaD
Amiloride—Aplastic anaemia—Methotrexate—colon cancer	0.00187	0.00608	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—CCND1—colon cancer	0.00184	0.0087	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—BRAF—colon cancer	0.00183	0.00862	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—CTNNB1—colon cancer	0.00183	0.00861	CbGpPWpGaD
Amiloride—Alopecia—Vincristine—colon cancer	0.00182	0.00593	CcSEcCtD
Amiloride—Coma—Methotrexate—colon cancer	0.00182	0.00592	CcSEcCtD
Amiloride—Urine output increased—Methotrexate—colon cancer	0.0018	0.00586	CcSEcCtD
Amiloride—Gynaecomastia—Methotrexate—colon cancer	0.00178	0.0058	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—FGFR3—colon cancer	0.00177	0.00837	CbGpPWpGaD
Amiloride—Alopecia—Irinotecan—colon cancer	0.00177	0.00577	CcSEcCtD
Amiloride—Orthostatic hypotension—Capecitabine—colon cancer	0.00177	0.00577	CcSEcCtD
Amiloride—Back pain—Vincristine—colon cancer	0.00173	0.00565	CcSEcCtD
Amiloride—PLAU—Endochondral Ossification—VEGFA—colon cancer	0.00173	0.00815	CbGpPWpGaD
Amiloride—PLAU—E2F transcription factor network—CDKN1A—colon cancer	0.00173	0.00814	CbGpPWpGaD
Amiloride—Flatulence—Irinotecan—colon cancer	0.00172	0.0056	CcSEcCtD
Amiloride—Muscular weakness—Capecitabine—colon cancer	0.00171	0.00557	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—EP300—colon cancer	0.0017	0.00801	CbGpPWpGaD
Amiloride—Alopecia—Fluorouracil—colon cancer	0.0017	0.00553	CcSEcCtD
Amiloride—Back pain—Irinotecan—colon cancer	0.00169	0.0055	CcSEcCtD
Amiloride—Abdominal distension—Capecitabine—colon cancer	0.00169	0.0055	CcSEcCtD
Amiloride—PLAU—Beta1 integrin cell surface interactions—VEGFA—colon cancer	0.00169	0.00795	CbGpPWpGaD
Amiloride—Muscle spasms—Irinotecan—colon cancer	0.00168	0.00547	CcSEcCtD
Amiloride—Polyuria—Methotrexate—colon cancer	0.00165	0.00536	CcSEcCtD
Amiloride—PLAU—E2F transcription factor network—EP300—colon cancer	0.00164	0.00774	CbGpPWpGaD
Amiloride—Angina pectoris—Capecitabine—colon cancer	0.00163	0.00532	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—APC—colon cancer	0.00163	0.00768	CbGpPWpGaD
Amiloride—Vertigo—Vincristine—colon cancer	0.00161	0.00525	CcSEcCtD
Amiloride—PLAU—Endochondral Ossification—TGFB1—colon cancer	0.00159	0.00748	CbGpPWpGaD
Amiloride—Vertigo—Irinotecan—colon cancer	0.00157	0.00511	CcSEcCtD
Amiloride—Dysuria—Capecitabine—colon cancer	0.00157	0.00511	CcSEcCtD
Amiloride—Neutropenia—Capecitabine—colon cancer	0.00157	0.00511	CcSEcCtD
Amiloride—SLC9A1—Disease—LGR5—colon cancer	0.00156	0.00734	CbGpPWpGaD
Amiloride—SLC9A1—Disease—CHST5—colon cancer	0.00156	0.00734	CbGpPWpGaD
Amiloride—PLAU—FGF signaling pathway—PIK3CA—colon cancer	0.00155	0.00729	CbGpPWpGaD
Amiloride—PLAU—Wnt Signaling Pathway—MYC—colon cancer	0.00153	0.00723	CbGpPWpGaD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—BRAF—colon cancer	0.00153	0.00722	CbGpPWpGaD
Amiloride—Visual disturbance—Methotrexate—colon cancer	0.00152	0.00496	CcSEcCtD
Amiloride—Cough—Irinotecan—colon cancer	0.00152	0.00496	CcSEcCtD
Amiloride—Depression—Capecitabine—colon cancer	0.00149	0.00486	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—MYC—colon cancer	0.00148	0.00698	CbGpPWpGaD
Amiloride—PLAU—AP-1 transcription factor network—TGFB1—colon cancer	0.00148	0.00696	CbGpPWpGaD
Amiloride—ASIC2—Transmembrane transport of small molecules—ABCB1—colon cancer	0.00147	0.00694	CbGpPWpGaD
Amiloride—Jaundice—Capecitabine—colon cancer	0.00146	0.00475	CcSEcCtD
Amiloride—Confusional state—Irinotecan—colon cancer	0.00144	0.00468	CcSEcCtD
Amiloride—PLAU—E2F transcription factor network—MYC—colon cancer	0.00143	0.00675	CbGpPWpGaD
Amiloride—Chest pain—Fluorouracil—colon cancer	0.00142	0.00464	CcSEcCtD
Amiloride—SLC9A1—G Protein Signaling Pathways—NRAS—colon cancer	0.0014	0.00662	CbGpPWpGaD
Amiloride—Shock—Irinotecan—colon cancer	0.0014	0.00457	CcSEcCtD
Amiloride—SLC9A1—Endothelins—HRAS—colon cancer	0.0014	0.00661	CbGpPWpGaD
Amiloride—Anorexia—Vincristine—colon cancer	0.00139	0.00454	CcSEcCtD
Amiloride—Confusional state—Fluorouracil—colon cancer	0.00138	0.00448	CcSEcCtD
Amiloride—Bradycardia—Capecitabine—colon cancer	0.00137	0.00445	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—CCND1—colon cancer	0.00136	0.00644	CbGpPWpGaD
Amiloride—Anorexia—Irinotecan—colon cancer	0.00136	0.00442	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—CTNNB1—colon cancer	0.00135	0.00637	CbGpPWpGaD
Amiloride—Haemoglobin—Capecitabine—colon cancer	0.00135	0.00439	CcSEcCtD
Amiloride—Haemorrhage—Capecitabine—colon cancer	0.00134	0.00437	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Vincristine—colon cancer	0.00133	0.00434	CcSEcCtD
Amiloride—Insomnia—Vincristine—colon cancer	0.00132	0.00431	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—SRC—colon cancer	0.00132	0.00624	CbGpPWpGaD
Amiloride—Paraesthesia—Vincristine—colon cancer	0.00131	0.00428	CcSEcCtD
Amiloride—SLC9A1—Metabolism—CHST5—colon cancer	0.0013	0.00615	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—ODC1—colon cancer	0.0013	0.00615	CbGpPWpGaD
Amiloride—Anorexia—Fluorouracil—colon cancer	0.0013	0.00424	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—CCND1—colon cancer	0.00129	0.0061	CbGpPWpGaD
Amiloride—Visual impairment—Capecitabine—colon cancer	0.00129	0.00421	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—CDKN1A—colon cancer	0.00129	0.00608	CbGpPWpGaD
Amiloride—Insomnia—Irinotecan—colon cancer	0.00129	0.0042	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—CTNNB1—colon cancer	0.00128	0.00604	CbGpPWpGaD
Amiloride—Paraesthesia—Irinotecan—colon cancer	0.00128	0.00417	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—NRAS—colon cancer	0.00127	0.006	CbGpPWpGaD
Amiloride—Decreased appetite—Vincristine—colon cancer	0.00127	0.00414	CcSEcCtD
Amiloride—Dyspnoea—Irinotecan—colon cancer	0.00127	0.00414	CcSEcCtD
Amiloride—Somnolence—Irinotecan—colon cancer	0.00127	0.00413	CcSEcCtD
Amiloride—Gastrointestinal disorder—Vincristine—colon cancer	0.00126	0.00411	CcSEcCtD
Amiloride—PLAU—FGF signaling pathway—AKT1—colon cancer	0.00126	0.00596	CbGpPWpGaD
Amiloride—Fatigue—Vincristine—colon cancer	0.00126	0.00411	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—EP300—colon cancer	0.00126	0.00593	CbGpPWpGaD
Amiloride—Dyspepsia—Irinotecan—colon cancer	0.00125	0.00408	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—CDKN1A—colon cancer	0.00125	0.0059	CbGpPWpGaD
Amiloride—Tinnitus—Capecitabine—colon cancer	0.00125	0.00408	CcSEcCtD
Amiloride—Pain—Vincristine—colon cancer	0.00125	0.00407	CcSEcCtD
Amiloride—Constipation—Vincristine—colon cancer	0.00125	0.00407	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00124	0.00405	CcSEcCtD
Amiloride—Decreased appetite—Irinotecan—colon cancer	0.00124	0.00403	CcSEcCtD
Amiloride—SLC9A1—Endothelins—AKT1—colon cancer	0.00124	0.00584	CbGpPWpGaD
Amiloride—Insomnia—Fluorouracil—colon cancer	0.00123	0.00402	CcSEcCtD
Amiloride—Gastrointestinal disorder—Irinotecan—colon cancer	0.00123	0.00401	CcSEcCtD
Amiloride—Fatigue—Irinotecan—colon cancer	0.00123	0.004	CcSEcCtD
Amiloride—Paraesthesia—Fluorouracil—colon cancer	0.00123	0.00399	CcSEcCtD
Amiloride—Pain—Irinotecan—colon cancer	0.00122	0.00397	CcSEcCtD
Amiloride—Constipation—Irinotecan—colon cancer	0.00122	0.00397	CcSEcCtD
Amiloride—Dyspnoea—Fluorouracil—colon cancer	0.00122	0.00396	CcSEcCtD
Amiloride—PLAU—AP-1 transcription factor network—TP53—colon cancer	0.00121	0.00573	CbGpPWpGaD
Amiloride—Somnolence—Fluorouracil—colon cancer	0.00121	0.00395	CcSEcCtD
Amiloride—SLC9A1—G Protein Signaling Pathways—KRAS—colon cancer	0.00121	0.00569	CbGpPWpGaD
Amiloride—Dyspepsia—Fluorouracil—colon cancer	0.0012	0.00391	CcSEcCtD
Amiloride—Gastrointestinal pain—Vincristine—colon cancer	0.0012	0.0039	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—SRC—colon cancer	0.00119	0.00563	CbGpPWpGaD
Amiloride—Decreased appetite—Fluorouracil—colon cancer	0.00119	0.00386	CcSEcCtD
Amiloride—Alopecia—Capecitabine—colon cancer	0.00119	0.00386	CcSEcCtD
Amiloride—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00118	0.00384	CcSEcCtD
Amiloride—Feeling abnormal—Irinotecan—colon cancer	0.00117	0.00382	CcSEcCtD
Amiloride—Neutropenia—Methotrexate—colon cancer	0.00117	0.0038	CcSEcCtD
Amiloride—Dysuria—Methotrexate—colon cancer	0.00117	0.0038	CcSEcCtD
Amiloride—Pain—Fluorouracil—colon cancer	0.00117	0.0038	CcSEcCtD
Amiloride—Gastrointestinal pain—Irinotecan—colon cancer	0.00117	0.00379	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—EGFR—colon cancer	0.00116	0.00547	CbGpPWpGaD
Amiloride—Abdominal pain—Vincristine—colon cancer	0.00116	0.00377	CcSEcCtD
Amiloride—Flatulence—Capecitabine—colon cancer	0.00115	0.00375	CcSEcCtD
Amiloride—Erectile dysfunction—Methotrexate—colon cancer	0.00115	0.00374	CcSEcCtD
Amiloride—Back pain—Capecitabine—colon cancer	0.00113	0.00368	CcSEcCtD
Amiloride—Abdominal pain—Irinotecan—colon cancer	0.00113	0.00367	CcSEcCtD
Amiloride—Feeling abnormal—Fluorouracil—colon cancer	0.00112	0.00366	CcSEcCtD
Amiloride—Muscle spasms—Capecitabine—colon cancer	0.00112	0.00366	CcSEcCtD
Amiloride—SLC9A1—Disease—AXIN2—colon cancer	0.00112	0.00527	CbGpPWpGaD
Amiloride—ASIC1—Transmembrane transport of small molecules—ABCB1—colon cancer	0.00112	0.00526	CbGpPWpGaD
Amiloride—SCNN1A—Transmembrane transport of small molecules—ABCB1—colon cancer	0.00112	0.00526	CbGpPWpGaD
Amiloride—SCNN1B—Transmembrane transport of small molecules—ABCB1—colon cancer	0.00112	0.00526	CbGpPWpGaD
Amiloride—SCNN1D—Transmembrane transport of small molecules—ABCB1—colon cancer	0.00112	0.00526	CbGpPWpGaD
Amiloride—SCNN1G—Transmembrane transport of small molecules—ABCB1—colon cancer	0.00112	0.00526	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—NRAS—colon cancer	0.00111	0.00526	CbGpPWpGaD
Amiloride—Depression—Methotrexate—colon cancer	0.00111	0.00361	CcSEcCtD
Amiloride—PLAU—Endochondral Ossification—AKT1—colon cancer	0.0011	0.0052	CbGpPWpGaD
Amiloride—SLC9A1—ErbB1 downstream signaling—KRAS—colon cancer	0.0011	0.00517	CbGpPWpGaD
Amiloride—Tremor—Capecitabine—colon cancer	0.00109	0.00357	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—MYC—colon cancer	0.00109	0.00516	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—TGFB1—colon cancer	0.00107	0.00503	CbGpPWpGaD
Amiloride—Vertigo—Capecitabine—colon cancer	0.00105	0.00342	CcSEcCtD
Amiloride—Asthenia—Vincristine—colon cancer	0.00105	0.00342	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—MYC—colon cancer	0.00104	0.0049	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—TGFB1—colon cancer	0.00104	0.00488	CbGpPWpGaD
Amiloride—Palpitations—Capecitabine—colon cancer	0.00103	0.00336	CcSEcCtD
Amiloride—SLC9A1—G Protein Signaling Pathways—HRAS—colon cancer	0.00103	0.00484	CbGpPWpGaD
Amiloride—Asthenia—Irinotecan—colon cancer	0.00102	0.00333	CcSEcCtD
Amiloride—Cough—Capecitabine—colon cancer	0.00102	0.00332	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—PIK3CA—colon cancer	0.00101	0.00475	CbGpPWpGaD
Amiloride—Haemoglobin—Methotrexate—colon cancer	0.001	0.00327	CcSEcCtD
Amiloride—Diarrhoea—Vincristine—colon cancer	0.001	0.00326	CcSEcCtD
Amiloride—Haemorrhage—Methotrexate—colon cancer	0.000999	0.00325	CcSEcCtD
Amiloride—Arthralgia—Capecitabine—colon cancer	0.000995	0.00324	CcSEcCtD
Amiloride—Chest pain—Capecitabine—colon cancer	0.000995	0.00324	CcSEcCtD
Amiloride—Diarrhoea—Irinotecan—colon cancer	0.000975	0.00318	CcSEcCtD
Amiloride—Dizziness—Vincristine—colon cancer	0.000968	0.00315	CcSEcCtD
Amiloride—Pruritus—Fluorouracil—colon cancer	0.000966	0.00314	CcSEcCtD
Amiloride—Visual impairment—Methotrexate—colon cancer	0.000963	0.00314	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—NRAS—colon cancer	0.000962	0.00454	CbGpPWpGaD
Amiloride—Confusional state—Capecitabine—colon cancer	0.000962	0.00313	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—KRAS—colon cancer	0.000959	0.00452	CbGpPWpGaD
Amiloride—Dizziness—Irinotecan—colon cancer	0.000942	0.00307	CcSEcCtD
Amiloride—Shock—Capecitabine—colon cancer	0.000938	0.00306	CcSEcCtD
Amiloride—Diarrhoea—Fluorouracil—colon cancer	0.000934	0.00304	CcSEcCtD
Amiloride—Tinnitus—Methotrexate—colon cancer	0.000932	0.00303	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—HRAS—colon cancer	0.000931	0.00439	CbGpPWpGaD
Amiloride—Vomiting—Vincristine—colon cancer	0.00093	0.00303	CcSEcCtD
Amiloride—Rash—Vincristine—colon cancer	0.000923	0.003	CcSEcCtD
Amiloride—Dermatitis—Vincristine—colon cancer	0.000922	0.003	CcSEcCtD
Amiloride—Headache—Vincristine—colon cancer	0.000917	0.00299	CcSEcCtD
Amiloride—Anorexia—Capecitabine—colon cancer	0.000909	0.00296	CcSEcCtD
Amiloride—Vomiting—Irinotecan—colon cancer	0.000906	0.00295	CcSEcCtD
Amiloride—Dizziness—Fluorouracil—colon cancer	0.000902	0.00294	CcSEcCtD
Amiloride—PLAU—Wnt Signaling Pathway and Pluripotency—TP53—colon cancer	0.000899	0.00424	CbGpPWpGaD
Amiloride—Rash—Irinotecan—colon cancer	0.000898	0.00293	CcSEcCtD
Amiloride—Dermatitis—Irinotecan—colon cancer	0.000898	0.00292	CcSEcCtD
Amiloride—Headache—Irinotecan—colon cancer	0.000893	0.00291	CcSEcCtD
Amiloride—Alopecia—Methotrexate—colon cancer	0.000883	0.00288	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—PIK3CA—colon cancer	0.000881	0.00416	CbGpPWpGaD
Amiloride—PLAU—Senescence and Autophagy in Cancer—TP53—colon cancer	0.000878	0.00414	CbGpPWpGaD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—EGFR—colon cancer	0.000877	0.00413	CbGpPWpGaD
Amiloride—Nausea—Vincristine—colon cancer	0.000869	0.00283	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000869	0.00283	CcSEcCtD
Amiloride—Vomiting—Fluorouracil—colon cancer	0.000868	0.00283	CcSEcCtD
Amiloride—Insomnia—Capecitabine—colon cancer	0.000863	0.00281	CcSEcCtD
Amiloride—Rash—Fluorouracil—colon cancer	0.00086	0.0028	CcSEcCtD
Amiloride—Dermatitis—Fluorouracil—colon cancer	0.00086	0.0028	CcSEcCtD
Amiloride—Paraesthesia—Capecitabine—colon cancer	0.000856	0.00279	CcSEcCtD
Amiloride—Headache—Fluorouracil—colon cancer	0.000855	0.00278	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—TP53—colon cancer	0.000852	0.00402	CbGpPWpGaD
Amiloride—Dyspnoea—Capecitabine—colon cancer	0.00085	0.00277	CcSEcCtD
Amiloride—Nausea—Irinotecan—colon cancer	0.000846	0.00276	CcSEcCtD
Amiloride—Back pain—Methotrexate—colon cancer	0.000841	0.00274	CcSEcCtD
Amiloride—PLAU—Senescence and Autophagy in Cancer—HRAS—colon cancer	0.00084	0.00396	CbGpPWpGaD
Amiloride—Dyspepsia—Capecitabine—colon cancer	0.000839	0.00273	CcSEcCtD
Amiloride—Decreased appetite—Capecitabine—colon cancer	0.000829	0.0027	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—KRAS—colon cancer	0.000828	0.00391	CbGpPWpGaD
Amiloride—Gastrointestinal disorder—Capecitabine—colon cancer	0.000823	0.00268	CcSEcCtD
Amiloride—SLC9A1—ErbB1 downstream signaling—AKT1—colon cancer	0.000822	0.00388	CbGpPWpGaD
Amiloride—Fatigue—Capecitabine—colon cancer	0.000822	0.00268	CcSEcCtD
Amiloride—Pain—Capecitabine—colon cancer	0.000816	0.00266	CcSEcCtD
Amiloride—Constipation—Capecitabine—colon cancer	0.000816	0.00266	CcSEcCtD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—HRAS—colon cancer	0.000815	0.00385	CbGpPWpGaD
Amiloride—Nausea—Fluorouracil—colon cancer	0.000811	0.00264	CcSEcCtD
Amiloride—Feeling abnormal—Capecitabine—colon cancer	0.000786	0.00256	CcSEcCtD
Amiloride—Vertigo—Methotrexate—colon cancer	0.000782	0.00255	CcSEcCtD
Amiloride—Gastrointestinal pain—Capecitabine—colon cancer	0.00078	0.00254	CcSEcCtD
Amiloride—SLC9A1—Regulation of Actin Cytoskeleton—PIK3CA—colon cancer	0.000761	0.00359	CbGpPWpGaD
Amiloride—Cough—Methotrexate—colon cancer	0.000759	0.00247	CcSEcCtD
Amiloride—Abdominal pain—Capecitabine—colon cancer	0.000754	0.00246	CcSEcCtD
Amiloride—Arthralgia—Methotrexate—colon cancer	0.000741	0.00241	CcSEcCtD
Amiloride—Chest pain—Methotrexate—colon cancer	0.000741	0.00241	CcSEcCtD
Amiloride—SLC9A1—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000735	0.00347	CbGpPWpGaD
Amiloride—PLAU—DNA Damage Response (only ATM dependent)—AKT1—colon cancer	0.00072	0.0034	CbGpPWpGaD
Amiloride—Confusional state—Methotrexate—colon cancer	0.000716	0.00233	CcSEcCtD
Amiloride—Asthenia—Capecitabine—colon cancer	0.000684	0.00223	CcSEcCtD
Amiloride—Anorexia—Methotrexate—colon cancer	0.000677	0.0022	CcSEcCtD
Amiloride—Pruritus—Capecitabine—colon cancer	0.000675	0.0022	CcSEcCtD
Amiloride—Diarrhoea—Capecitabine—colon cancer	0.000653	0.00213	CcSEcCtD
Amiloride—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000647	0.00211	CcSEcCtD
Amiloride—Insomnia—Methotrexate—colon cancer	0.000642	0.00209	CcSEcCtD
Amiloride—Paraesthesia—Methotrexate—colon cancer	0.000637	0.00208	CcSEcCtD
Amiloride—Dyspnoea—Methotrexate—colon cancer	0.000633	0.00206	CcSEcCtD
Amiloride—Somnolence—Methotrexate—colon cancer	0.000631	0.00206	CcSEcCtD
Amiloride—Dizziness—Capecitabine—colon cancer	0.000631	0.00205	CcSEcCtD
Amiloride—Dyspepsia—Methotrexate—colon cancer	0.000625	0.00204	CcSEcCtD
Amiloride—Decreased appetite—Methotrexate—colon cancer	0.000617	0.00201	CcSEcCtD
Amiloride—Gastrointestinal disorder—Methotrexate—colon cancer	0.000613	0.002	CcSEcCtD
Amiloride—Fatigue—Methotrexate—colon cancer	0.000612	0.00199	CcSEcCtD
Amiloride—Pain—Methotrexate—colon cancer	0.000607	0.00198	CcSEcCtD
Amiloride—Vomiting—Capecitabine—colon cancer	0.000606	0.00197	CcSEcCtD
Amiloride—Rash—Capecitabine—colon cancer	0.000601	0.00196	CcSEcCtD
Amiloride—Dermatitis—Capecitabine—colon cancer	0.000601	0.00196	CcSEcCtD
Amiloride—Headache—Capecitabine—colon cancer	0.000597	0.00195	CcSEcCtD
Amiloride—Feeling abnormal—Methotrexate—colon cancer	0.000585	0.00191	CcSEcCtD
Amiloride—Gastrointestinal pain—Methotrexate—colon cancer	0.000581	0.00189	CcSEcCtD
Amiloride—Nausea—Capecitabine—colon cancer	0.000566	0.00184	CcSEcCtD
Amiloride—Abdominal pain—Methotrexate—colon cancer	0.000561	0.00183	CcSEcCtD
Amiloride—Asthenia—Methotrexate—colon cancer	0.000509	0.00166	CcSEcCtD
Amiloride—Pruritus—Methotrexate—colon cancer	0.000502	0.00164	CcSEcCtD
Amiloride—Diarrhoea—Methotrexate—colon cancer	0.000486	0.00158	CcSEcCtD
Amiloride—Dizziness—Methotrexate—colon cancer	0.000469	0.00153	CcSEcCtD
Amiloride—SLC22A2—Metabolism—CA7—colon cancer	0.000466	0.0022	CbGpPWpGaD
Amiloride—Vomiting—Methotrexate—colon cancer	0.000451	0.00147	CcSEcCtD
Amiloride—Rash—Methotrexate—colon cancer	0.000448	0.00146	CcSEcCtD
Amiloride—Dermatitis—Methotrexate—colon cancer	0.000447	0.00146	CcSEcCtD
Amiloride—Headache—Methotrexate—colon cancer	0.000445	0.00145	CcSEcCtD
Amiloride—SLC22A1—Metabolism—CA7—colon cancer	0.000434	0.00205	CbGpPWpGaD
Amiloride—Nausea—Methotrexate—colon cancer	0.000422	0.00137	CcSEcCtD
Amiloride—PLAU—Hemostasis—EP300—colon cancer	0.000349	0.00165	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—ABCB1—colon cancer	0.000344	0.00162	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—SRC—colon cancer	0.000339	0.0016	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—TYMS—colon cancer	0.000338	0.0016	CbGpPWpGaD
Amiloride—SLC22A4—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000337	0.00159	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—VEGFA—colon cancer	0.00033	0.00156	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—NRAS—colon cancer	0.000326	0.00154	CbGpPWpGaD
Amiloride—SLC9A1—Disease—FGFR3—colon cancer	0.000323	0.00152	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—TGFB1—colon cancer	0.000303	0.00143	CbGpPWpGaD
Amiloride—SLC9A1—Disease—APC—colon cancer	0.000296	0.0014	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—ODC1—colon cancer	0.000282	0.00133	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—CHST5—colon cancer	0.000282	0.00133	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—KRAS—colon cancer	0.000281	0.00132	CbGpPWpGaD
Amiloride—SLC9A1—Disease—BRAF—colon cancer	0.000279	0.00131	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—CHST5—colon cancer	0.000263	0.00124	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—ODC1—colon cancer	0.000263	0.00124	CbGpPWpGaD
Amiloride—SLC22A2—Transmission across Chemical Synapses—BRAF—colon cancer	0.000262	0.00123	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—PIK3CA—colon cancer	0.000258	0.00122	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—TP53—colon cancer	0.00025	0.00118	CbGpPWpGaD
Amiloride—SLC22A1—Transmission across Chemical Synapses—BRAF—colon cancer	0.000244	0.00115	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PPARG—colon cancer	0.00024	0.00113	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—HRAS—colon cancer	0.000239	0.00113	CbGpPWpGaD
Amiloride—SLC9A1—Disease—PTGS2—colon cancer	0.000225	0.00106	CbGpPWpGaD
Amiloride—PLAU—Hemostasis—AKT1—colon cancer	0.000211	0.000994	CbGpPWpGaD
Amiloride—SLC9A1—Disease—CTNNB1—colon cancer	0.000201	0.00095	CbGpPWpGaD
Amiloride—SLC22A2—Neuronal System—BRAF—colon cancer	0.000201	0.000946	CbGpPWpGaD
Amiloride—SLC9A1—Disease—CDKN1A—colon cancer	0.000197	0.000928	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PTGS2—colon cancer	0.000189	0.000889	CbGpPWpGaD
Amiloride—SLC9A1—Disease—EP300—colon cancer	0.000187	0.000883	CbGpPWpGaD
Amiloride—SLC22A1—Neuronal System—BRAF—colon cancer	0.000187	0.000882	CbGpPWpGaD
Amiloride—SLC9A1—Disease—SRC—colon cancer	0.000182	0.000859	CbGpPWpGaD
Amiloride—SLC9A1—Disease—NRAS—colon cancer	0.000175	0.000826	CbGpPWpGaD
Amiloride—SLC9A1—Disease—MYC—colon cancer	0.000163	0.00077	CbGpPWpGaD
Amiloride—SLC9A1—Disease—TGFB1—colon cancer	0.000163	0.000768	CbGpPWpGaD
Amiloride—SLC9A1—Disease—EGFR—colon cancer	0.00016	0.000753	CbGpPWpGaD
Amiloride—SLC22A2—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000159	0.000751	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—EP300—colon cancer	0.000157	0.00074	CbGpPWpGaD
Amiloride—SLC9A1—Disease—KRAS—colon cancer	0.000151	0.000711	CbGpPWpGaD
Amiloride—SLC22A1—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000148	0.0007	CbGpPWpGaD
Amiloride—SLC9A1—Disease—PIK3CA—colon cancer	0.000138	0.000653	CbGpPWpGaD
Amiloride—SLC9A1—Disease—HRAS—colon cancer	0.000128	0.000604	CbGpPWpGaD
Amiloride—SLC22A2—Transmission across Chemical Synapses—HRAS—colon cancer	0.00012	0.000568	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—PIK3CA—colon cancer	0.000116	0.000547	CbGpPWpGaD
Amiloride—SLC9A1—Disease—AKT1—colon cancer	0.000113	0.000534	CbGpPWpGaD
Amiloride—SLC22A1—Transmission across Chemical Synapses—HRAS—colon cancer	0.000112	0.000529	CbGpPWpGaD
Amiloride—SLC9A1—Metabolism—AKT1—colon cancer	9.47e-05	0.000447	CbGpPWpGaD
Amiloride—SLC22A2—Neuronal System—HRAS—colon cancer	9.22e-05	0.000435	CbGpPWpGaD
Amiloride—SLC22A1—Neuronal System—HRAS—colon cancer	8.6e-05	0.000405	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—ABCB1—colon cancer	7.46e-05	0.000352	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—TYMS—colon cancer	7.32e-05	0.000345	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—ABCB1—colon cancer	6.95e-05	0.000328	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—TYMS—colon cancer	6.82e-05	0.000322	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PPARG—colon cancer	5.19e-05	0.000245	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PPARG—colon cancer	4.83e-05	0.000228	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PTGS2—colon cancer	4.08e-05	0.000192	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PTGS2—colon cancer	3.8e-05	0.000179	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—EP300—colon cancer	3.39e-05	0.00016	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—EP300—colon cancer	3.16e-05	0.000149	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—PIK3CA—colon cancer	2.51e-05	0.000118	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—PIK3CA—colon cancer	2.34e-05	0.00011	CbGpPWpGaD
Amiloride—SLC22A2—Metabolism—AKT1—colon cancer	2.05e-05	9.67e-05	CbGpPWpGaD
Amiloride—SLC22A1—Metabolism—AKT1—colon cancer	1.91e-05	9.02e-05	CbGpPWpGaD
